Knochenstoffwechsel in der Onkologie

Zusammenfassung

Veränderungen im Knochenstoffwechsel in der Onkologie sind nicht nur von Bedeutung durch die Bildung von Knochenmetastasen als Folge von Primärerkrankungen wie Mammakarzinom oder Prostatakrebs, sondern treten in jüngster Zeit auch in den Blickpunkt aufgrund der adjuvanten Therapie des Mammakarzinoms, besonders mit den Aromatasehemmern, die zu einer ausgeprägten Östrogendeprivation führen. Ziel dieser Übersichtsarbeit ist es, neben dem aktuellen Stand der Forschung auch Überblicke über Diagnose und Behandlungsstrategie hinsichtlich Veränderungen des Knochenstoffwechsels im Bereich der Onkologie zu geben.

Abstract

Changes in bone metabolism in oncological patients have a clinical significance for the formation of bone metastasis during the course of primary diseases such as breast cancer or prostate cancer. In addition, attention is currently being focused on bone metabolism changes during adjuvant therapies for breast cancer, especially after the administration of aromatase inhibitors which lead to estrogen deprivation. The aim of the present review is to give an overview of the current scientific state of the art together with a summary on the diagnosis and treatment strategies with respect to changes of bone metabolism in oncology.

Knochenstoffwechsel - Onkologie - Diagnose - Therapie

bone metabolism - oncology - diagnosis - therapy

Literatur

• 1 Coleman R E, Rubens R D. The clinical course of bone metastases from breast cancer.  Br J Cancer. 1987;  55 61-66
• 2 Solomayer E-F, Diel I J, Wallwiener D, Bastert G. Das primär ossär metastasierte Mammakarzinom. Untersuchungen zu Prognose, Verlauf und Therapie.  Geburtsh Frauenheilk. 1997;  57 629-636
• 3 Solomayer E-F, Diel I J, Gollan C, Bastert G. Localization of the first metastases in breast cancer. Analysis to clinical course, prognosis and therapy.  Breast Cancer Res Treat Cancer. 2000;  59 271-278
• 4 Coleman R E, Seaman J J. The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases.  Semin Oncol. 2001;  28 11-16
• 5 Käkönen S-M, Mundy G R. Mechanisms of osteolytic bone metastases in breast carcinoma.  Cancer. 2003;  97 834-839
• 6 Guise T A, Yin J J, Mohammad K S. Role of endothelin-1 in osteoblastic bone metastases.  Cancer. 2003;  97 779-784
• 7 Demers L M, Costa L, Chincilli V, Gaydos L, Curley E, Lipton A. Biochemical markers of bone turnover in patients with metastatic bone disease.  Clin Chem. 1995;  41 1489-1494
• 8 Yoneda T, Hashimoto N, Hiraga T. Bisphosphonate actions on cancer.  Calcif Tissue Int. 2003;  73 315-318
• 9 Bolotin H H. Inaccuracies inherent in dual-energy X‐ray absorptiometry in vivo bone mineral densitometry may flaw osteopenic / osteoporotic interpretations and mislead assessment of antiresorptive therapy effectiveness.  Bone. 2001;  28 548-555
• 10 Dachverband Osteologie e.V. (DVO) .Evidenzbasierte Konsensus-Leitlinie zur Osteoporose. Stuttgart; Schattauer Verlag 2006
• 11 Wüster C, Heilmann P, Pereira-Lima J, Schlegel J, Anstätt K, Soballa T. Quantitative ultrasonometry (QUS) for the evaluation of osteoporosis risk: reference data for various measurement sites, limitations and application possibilities.  Exp Clin Endocrinol Diabetes. 1998;  106 277-288
• 12 Hadji P, Hars O, Wüster C, Bock K, Alberts U S, Bohnet H G, Emons G, Schulz K D. Stiffness index identifies patients with osteoporotic fractures better than ultrasound velocity or attenuation alone.  Maturitas. 1999;  31 221-226
• 13 Kann P H. Bone densitometry and ultrasound studies of the bone: methods, indications and efficacy.  Orthopäde. 2001;  30 437-443
• 14 Kraemer D F, Nelson H D, Bauer D C, Helfand M. Economic comparison of diagnostic approaches for evaluating osteoporosis in older women.  Osteoporos Int. 2006;  17 68-76
• 15 Marín F, González-Macías J, Díez-Pérez A, Palma S, Delgado-Rodríguez M. Relationship between bone quantitative ultrasound and fractures: a meta-analysis.  J Bone Miner Res. 2006;  21 1126-1135
• 16 Hadji P. Possibilities and limitations of quantitative ultrasonometry in clinical practice.  Dtsch Med Wochenschr. 2003;  128 951-953
• 17 Vehmanen L, Saarto T, Elomaa I, Mäkelä P, Välimäki M, Blomqvist C. Long-term impact of chemotherapyinduced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment.  Eur J Cancer. 2001;  37 2373-2378
• 18 Gnant M FX, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.  J Clin Oncol. 2007;  25 820-828
• 19 Pfeilschifter J, Diehl I. Osteoporosis due to cancer treatment: pathogenesis and management.  J Clin Onc. 2000;  18 1570-1593
• 20 Lower E E, Blau R, Gazder P, Tummala R. The risk of premature menopause induced by chemotherapy for early breast cancer.  J Women's Health. 1999;  8 949-954
• 21 Ataya K, Moghissi K. Chemotherapy induced premature ovarian failure: Mechanisms and prevention.  Steroids. 1989;  54 607-626
• 22 Howell S J, Berger G, Adams J E, Shalet S M. Bone mineral density in women with cytotoxicinduced ovarian failure.  Clin Endocrin. 1998;  49 397-402
• 23 LeBoff M S, Neuberg D, Fowler K, Shapiro C L. Chemotherapy-induced amenorrhea in women with breast cancer leads to marked bone loss.  Bone. 1998;  23 621
• 24 Headley J A, Theriault R L, LeBlanc A D, Vassilopoulou-Sellin R, Hortobagyi G N. Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy.  Cancer Investigation. 1998;  16 6-11
• 25 Shapiro C L, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer.  J Clin Oncol. 2001;  19 3306-3311
• 26 Davies J H, Evans B AJ, Jenney M EM, Gregory J W. In vitro effects of chemotherapeutic agents on human osteoblast-like cells.  Calcif Tissue Int. 2002;  70 408-415
• 27 Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group . Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.  Cancer. 2003;  98 1802-1810
• 28 Eastell R, Hannon R A, Cuzick J, Dowsett M, Clack G, Adams J E. ATAC Trialists' group. Effect of an aromatase inhibitor on bmd ad bone turnover markers: 2-year results of Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial.  J Bone Miner Res. 2006;  21 1215-1223
• 29 Thurlimann B, Keshaviah A, Coates A S, Mouridsen H, Mauriac L, Forbes J F, Paridaens R, Castiglione-Gertsch M, Gelber R D, Rabaglio M, Smith I, Wardley A, Price K N, Goldhirsch A. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.  N Engl J Med. 2005;  353 2747-2757
• 30 Jones S E, Cantrell J, Vukelja S, Pippen J, O'Shaughnessy J, Blum J L, Brooks R, Hartung N L, Negron A G, Richards D A, Rivera R, Holmes F A, Chittoor S, Whittaker T L, Bordelon J H, Ketchel S J, Davis J C, Ilegbodu D, Kochis J, Asmar L. The effect of tamoxifen (T) or exemestane (E) on bone mineral density (BMD) after 1 year of adjuvant treatment of postmenopausal women with early breast cancer.  J Clin Oncol. 2005;  23 31s
• 31 Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J. Switching of postmenopausal women with endocrineresponsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial.  Lancet. 2005;  366 455-462
• 32 Coombes R C, Kilburn L S, Paridaens R, Coleman R E, Jones S E, Jassem J, Van de Velde C J, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates A S, Bajetta E, Holmberg S B, Dodwell D, Mickiewicz E, Andersen J, Lønning P E, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield L J, Bertelli G, Hall E, Bogle R G, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss J M. Survival and safety of exemestane versus tamoxifen after 2 – 3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.  Lancet. 2007;  369 559-570
• 33 Goss P E, Ingle J N, Martino S, Robert N J, Muss H B, Piccart M J, Castiglione M, Tu D, Shepherd L E, Pritchard K I, Livingston R B, Davidson N E, Norton L, Perez E A, Abrams J S, Therasse P, Palmer M J, Pater J L. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.  N Engl J Med. 2003;  349 1793-1802
• 34 Perez E A, Josse R G, Pritchard K I, Ingle J N, Martino S, Findlay B P, Shenkier T N, Tozer R G, Palmer M J, Shepherd L E, Liu S, Tu D, Goss P E. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCIC CTG MA.17.  J Clin Oncol. 2006;  24 3629-3635
• 35 Love R R, Mazess R B, Barden H S, Epstein S, Newcomb P A, Jordan V C, Carbone P P, DeMets D L. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer.  N Engl J Med. 1992;  326 852-856
• 36 Powles T J, McCloskey E, Paterson A H, Ashley S, Tidy V A, Nevantaus A, Rosenqvist K, Kanis J. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer.  J Natl Cancer Inst. 1998;  90 704-708
• 37 Hillner B E, Ingle J N, Chlebowski Gralow R TJ, Yee G C, Janjan N A, Cauley J A, Blumenstein B A, Albain K S, Lipton A, Brown S. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer.  J Clin Oncol. 2003;  21 4042-4047
• 38 Hadji P, Aapro M, Brufsky A, Tubiana-Hulin Guise A T, Body J J. Practical guidance for the prevention of aromatase inhibitor-associated bone loss in women with breast cancer.  Breast Cancer Res Treat. 2007;  106, Suppl 1 Abstract 504
• 39 Brufsky A, Harker W G, Beck J T, Carroll R, Tan-Chiu E, Seidler C, Hohneker J, Lacerna L, Petrone S, Perez E A. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.  J Clin Oncol. 2007;  25 3194-3197